Scan­dion's shares fall af­ter on­col­o­gy biotech re­ports PhII fail

Dan­ish biotech Scan­dion On­col­o­gy post­ed some Phase II re­sults on Fri­day, and in­vestors were none too pleased.

The biotech re­port­ed topline re­sults from the sec­ond part of an on­go­ing Phase II tri­al called CORIST. The study was in­ves­ti­gat­ing Scan­dion’s lead can­di­date SCO-101 in 25 pa­tients as a com­bi­na­tion treat­ment with FOLFIRI chemother­a­py in metasta­t­ic col­orec­tal can­cer. And so far, the study did not meet the biotech’s pri­ma­ry end­point: tu­mor re­duc­tion of at least 30%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER